GlaxoSmithKline plc (GSK.L)
-LSE 1,657.00 
5.00(0.30%) 11:35AM EDT
| Prev Close: | 1,662.00 |
|---|
| Open: | 1,657.50 |
|---|
| Bid: | 1,656.50 |
|---|
| Ask: | 1,657.50 |
|---|
| 1y Target Est: | 1,608.40 |
|---|
| Beta: | N/A |
|---|
| Next Earnings Date: | N/A |
|---|
| Day's Range: | 1,645.00 - 1,661.50 |
|---|
| 52wk Range: | 1,314.00 - 1,695.00 |
|---|
| Volume: | 4,498,790 |
|---|
| Avg Vol (3m): | 7,588,310 |
|---|
| Market Cap: | 80.27B |
|---|
| P/E (ttm): | 1,947.12 |
|---|
| EPS (ttm): | 0.85 |
|---|
| Div & Yield: | N/A (N/A) |
|---|
Quotes delayed, except where indicated otherwise. Currency in GBp.
Headlines
- Aveo Fails to Win FDA Panel Backing for Kidney Cancer Drugat Bloomberg(Thu 1:05PM EDT)
- JP Morgan, Greenhill advising GSK on sale of soft drinks brandsat Reuters(Thu 4:58AM EDT)
- Glaxo Mined Online Parent Discussion Boards For Vaccine Worriesat The Wall Street Journal(Wed, May 1)
- Consumers in India Are an M&A Targetat The Wall Street Journal(Wed, May 1)
- Is GlaxoSmithKline an Exciting Emerging Market Play?at Motley Fool(Tue, Apr 30)
- Merck’s HPV Vaccine May Protect Girls With Fewer Dosesat Bloomberg(Tue, Apr 30)
- BRIEF-GSK makes regulatory submission for umeclidinium monotherapy in U.S.at Reuters(Tue, Apr 30)
- Unilever to raise stake in Indian unit in $5.4 billion offerat Reuters(Tue, Apr 30)
- Why GlaxoSmithKline Is Up 24% During the Last 12 Monthsat Motley Fool(Mon, Apr 29)
- Impax, GSK end Parkinson's disease partnershipat Reuters(Mon, Apr 29)
- UPDATE 1-FDA raises concerns on seizure drug of Valeant, Glaxoat Reuters(Fri, Apr 26)
- FDA raises safety concerns on Valeant's seizure drugat Reuters(Fri, Apr 26)
- Theravance to Split After Ending Review of Alternativesat Bloomberg(Fri, Apr 26)
- To GlaxoSmithKline, an Apologyat Motley Fool(Fri, Apr 26)
- BRIEF-GlaxoSmithKline reports submission for UMEC in EUat Reuters(Fri, Apr 26)
Key Statistics
| Forward P/E (1 yr): | 0.13 |
|---|
| P/S (ttm): | 306.55 |
|---|
| Ex-Dividend Date: | N/A |
|---|
Analysts
| Annual EPS Est
(Dec-13)
: | 114.31 |
|---|
| Quarterly EPS Est
(Jun-13)
: | 28.66 |
|---|
| Mean Recommendation*: | 2.6 |
|---|
| PEG Ratio (5 yr expected): | 1.91 |
|---|
Business Summary
GlaxoSmithKline plc, together with its subsidiaries, discovers, develops, manufactures, and markets pharmaceutical products, over-the-counter medicines, and health-related consumer products worldwide.
View More